GE HealthCare is gaining ground with strong backlog, AI-driven imaging advances and rising service capture, while Hologic's buyout caps near-term upside.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
HOLX's $18.3B Blackstone-TPG buyout nears close after Q1 miss. With shares near a $76 cash offer, the upside for HOLX investors looks dim.
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN Surgical growth.
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) came out with quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.03 per share a year ago.
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
HOLX heads into Q1 earnings with rising EPS and revenue estimates, strong segment momentum and a pending buyout limiting near-term upside.
Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.